PD-1 INHIBITOR
Clinical trials for PD-1 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PD-1 INHIBITOR trials appear
Sign up with your email to follow new studies for PD-1 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on hard-to-treat pancreatic cancer
Disease control Recruiting nowThis study tests whether adding low-dose radiation and an immunotherapy drug (pultelimab) to standard treatment can help control advanced pancreatic cancer. About 10 adults who have not had prior immunotherapy will receive the combination. The goal is to see if the treatment shri…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Kidney-Sparing drug combo offers hope for renal pelvic cancer patients
Disease control Recruiting nowThis study tests a combination of two drugs (tislelizumab and nab-paclitaxel) to treat a type of kidney cancer called renal pelvic cancer. The goal is to control the disease while saving the kidney, avoiding the need for full kidney removal. About 35 adults with early-stage cance…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated May 12, 2026 13:41 UTC